RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ascendis Pharma A/S - Stock

Ascendis Pharma A/S ROA 2024

Ascendis Pharma A/S ROA

-0.58

Ticker

ASND

ISIN

US04351P1012

WKN

A14M6X

In 2024, Ascendis Pharma A/S's return on assets (ROA) was -0.58, a 8.96% increase from the -0.54 ROA in the previous year.

Ascendis Pharma A/S Aktienanalyse

What does Ascendis Pharma A/S do?

Ascendis Pharma A/S is a biopharmaceutical company based in Denmark that focuses on developing innovative therapies for diseases that currently have no suitable treatment options. The company was founded in 2007 and is headquartered in Hellerup, Denmark. History The company was founded by an experienced team of researchers and professionals from the pharmaceutical and biotech industry who recognized the need for new therapies for chronic diseases. They used innovative technologies to develop drugs that would have longer-lasting effects, thus reducing the need for frequent doses. In 2015, the company went public to raise additional capital for the further development of their technologies and products. Business model Ascendis Pharma A/S is working on the development of drugs using a proprietary technology platform called TransCon technology. TransCon technology is a novel delivery system that allows drugs to remain in the body for longer periods of time, thus achieving a continuous effect. This leads to a reduced need for frequent doses, improving patient care and adherence to therapy. The company follows an asset-based business model strategy. It aims to market its products globally through a licensing and partnering approach. By partnering with established pharmaceutical companies, Ascendis Pharma A/S can introduce their drugs into broader markets while ensuring resources for further research and development. Divisions Ascendis Pharma A/S has two main business divisions: 1. Endocrinology: Ascendis Pharma A/S is a leader in the development of therapies for diseases caused by hormonal disorders. The TransCon technology is used for the delivery of hormones such as growth hormone, parathyroid hormone, follicle-stimulating hormone, and luteinizing hormone to achieve continuous release in the body. 2. Oncology: The company also utilizes the TransCon technology for the delivery of cytokines for cancer immunotherapy. Products The most well-known product of Ascendis Pharma A/S is TransCon Growth Hormone, a growth hormone therapy that has longer-lasting effects and only needs to be administered once a week for children with growth hormone deficiency. The company also has TransCon PTH and TransCon CNP in the endocrinology pipeline. In oncology, the company has developed TransCon IL-2, an interleukin-2 immunotherapy for cancer. Summary Ascendis Pharma A/S is an innovative biopharmaceutical company specializing in the development of therapies for chronic diseases. The company utilizes its proprietary technology platform, TransCon technology, to develop drugs that have longer-lasting effects and reduce the need for frequent doses. It focuses on endocrinology and oncology and follows an asset-based business model strategy by entering partnerships with established pharmaceutical companies. The most well-known product of Ascendis Pharma A/S is TransCon Growth Hormone. Ascendis Pharma A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Ascendis Pharma A/S's Return on Assets (ROA)

Ascendis Pharma A/S's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Ascendis Pharma A/S's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Ascendis Pharma A/S's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Ascendis Pharma A/S’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Ascendis Pharma A/S stock

What is the Return on Assets (ROA) of Ascendis Pharma A/S this year?

The Return on Assets (ROA) of Ascendis Pharma A/S is -0.58 undefined this year.

What was the ROA of Ascendis Pharma A/S compared to the previous year?

The ROA of Ascendis Pharma A/S has increased by 8.96% compared to the previous year.

What consequences do high ROA have for investors of Ascendis Pharma A/S?

A high ROA is advantageous for investors of Ascendis Pharma A/S, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Ascendis Pharma A/S?

A low ROA can be unfavorable for investors of Ascendis Pharma A/S as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Ascendis Pharma A/S affect the company?

An increase in ROA of Ascendis Pharma A/S can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Ascendis Pharma A/S impact the company?

A reduction in the ROA of Ascendis Pharma A/S can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Ascendis Pharma A/S?

Some factors that can influence the ROA of Ascendis Pharma A/S include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Ascendis Pharma A/S important for investors?

The ROA of Ascendis Pharma A/S is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Ascendis Pharma A/S take to improve ROA?

To improve ROA, Ascendis Pharma A/S can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Ascendis Pharma A/S pay?

Over the past 12 months, Ascendis Pharma A/S paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ascendis Pharma A/S is expected to pay a dividend of 0 EUR.

What is the dividend yield of Ascendis Pharma A/S?

The current dividend yield of Ascendis Pharma A/S is .

When does Ascendis Pharma A/S pay dividends?

Ascendis Pharma A/S pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ascendis Pharma A/S?

Ascendis Pharma A/S paid dividends every year for the past 0 years.

What is the dividend of Ascendis Pharma A/S?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ascendis Pharma A/S located?

Ascendis Pharma A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ascendis Pharma A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ascendis Pharma A/S from 7/10/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 7/10/2024.

When did Ascendis Pharma A/S pay the last dividend?

The last dividend was paid out on 7/10/2024.

What was the dividend of Ascendis Pharma A/S in the year 2023?

In the year 2023, Ascendis Pharma A/S distributed 0 EUR as dividends.

In which currency does Ascendis Pharma A/S pay out the dividend?

The dividends of Ascendis Pharma A/S are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Ascendis Pharma A/S stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Ascendis Pharma A/S

Our stock analysis for Ascendis Pharma A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ascendis Pharma A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.